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Abstract
Background: Delirium is common in elderly inpatients, causing distress, cognitive
decline and death. No known intervention improves the course of delirium; current
treatments are symptomatic, and limited by lack of efficacy and adverse effects. There is
an urgent need to find an effective treatment for delirium.
Aims: To determine the feasibility of a trial of oral melatonin 5 mg nightly for
five nights for the treatment of delirium in older medical inpatients, and determine the
participants required to demonstrate a clinically and statistically significant decrease in
severity of delirium in older medical inpatients treated with melatonin.
Methods: This was a double blinded, randomised controlled trial in general internal
medicine units of a tertiary teaching hospital. Older (≥70 years) inpatients with confu-
sion assessment method positive hyperactive or mixed delirium were suitable for inclu-
sion. Subjects received melatonin 5 mg oral nightly for five nights or matching placebo.
The primary outcome was the Memorial Delirium Assessment Scale (MDAS) adminis-
tered daily.
Results: No adverse effects occurred due to melatonin. In the treatment group, the
mean change in MDAS from baseline during treatment period was 2.5  5.0 points, in
the placebo group, 2.1  4.1 points, a non-significant difference. A power calculation
accounting for drop-out (31.0%), suggests 120 participants would be required to dem-
onstrate with 90% power that melatonin 5 mg reduces the severity of delirium by
3 points or more on MDAS.
Conclusions: A trial of the hypothesis that 5 mg melatonin nightly for five nights reduces
delirium severity in older medical inpatients would require 120 patients, and is feasible.
Introduction
Delirium is a common condition affecting up to one fifth
of hospitalised older adults1,2 and often undiagnosed.3 It is
associated with poor outcomes, including long-term cog-
nitive decline,4 functional decline,5 institutionalisation6
and mortality.7 Delirium is a syndrome with an acute,
fluctuating course with disturbance of attention, aware-
ness, psychomotor state and perception.8 Pharmacological
treatments shown to be a mildly effective symptomatic
treatment include antipsychotics, although they are asso-
ciated with adverse effects.9,10 Other agents are not rec-
ommended due to lack of evidence of efficacy and, or
adverse effects.11 Disturbance of sleep and circadian
rhythm is common in delirium, where sleep–wake cycle
reversal, hypersomnolence, and hyperactivity are all
recognised phenomena,12 and a potential mechanism
links delirium and sleep.13
Melatonin (N-acetyl-5-methoxytryptamine) is a hor-
mone and neurotransmitter derived from the pineal
gland that regulates circadian rhythm. Abnormalities of
melatonin physiology have been demonstrated in delir-
ium. Low levels of urinary metabolites have been found
in hyperactive delirious patients, whereas high levels
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were associated with hypoactive motor states,14–16
suggesting a melatonin deficiency in hyperactive but not
hypoactive delirium. Abnormalities of tryptophan (from
which melatonin is derived) metabolism including low
metabolites suggestive of low melatonin secretion are
associated with post-operative and critical care delir-
ium.17,18 Case reports of successful treatment of delirium
with melatonin have been published,14 but no
randomised controlled trials of melatonin for the treat-
ment of delirium. Some indications of the efficacy of
melatonin for the treatment of delirium can be derived
from studies of incident delirium where melatonin was
continued if delirium occurred. In a trial of 0.5 mg in
medical inpatients melatonin decreased delirium inci-
dence but had no effect on delirium severity when it
developed.19 Sultan et al. conducted a trial of 5 mg mela-
tonin versus no treatment, clonidine or midazolam pre-
operatively for hip arthroplasty also reported reduced
delirium incidence.20 Melatonin was continued for
three nights if delirium developed; this was reported to
be effective for treatment of delirium that occurred but
no validated scale or control was used.20 In contrast, a
trial of 3 mg in fractured neck of femur patients showed
no effect on delirium incidence or severity.21 Thus, the
evidence for melatonin for as effective and the appropri-
ate dose for the treatment of delirium is unclear. Melato-
nin currently cannot be recommended for the treatment
of delirium on the basis of current evidence.
We aimed to determine the feasibility of, and number
of participants required in, a study that would determine
if 5 mg melatonin nightly for five nights reduces the
severity of delirium in medical inpatients with delirium.
Methods
Trial design
The protocol of this trial has previously been published
elsewhere.22 This was a single-centre, randomised,
placebo-controlled trial of 5 mg melatonin or placebo for
five nights with an additional two nights of follow-up
between May 2014 and June 2016. The study was con-
ducted after approval by the Human Research Ethics
Committee at the Royal Melbourne Hospital, Australia,
and was conducted in concordance with Good Clinical
Practice guidelines. Patients with delirium are generally
considered to lack the capacity to consent. As such, writ-
ten informed consent was provided by a surrogate deci-
sion maker who could provide legal consent that would
hold until the patient’s capacity to consent returned. The
trial is registered with the Australia New Zealand Clinical
Trials Registry (trial ID: ACTRN12614000101684). There
were no changes to the trial or protocol once it had
started. The trial and reporting conforms to CONSORT
guidelines.
Participants and setting
The study was conducted at The Royal Melbourne Hospi-
tal, Parkville, Australia, a 550-bed acute teaching hospital.
The study population consisted of general medical inpa-
tients aged 70 years or older. Potential participants were
identified by discussion of new admissions to the units at
handover meetings and referral by medical staff of units
following information and advertisement of the trial.
Patients were screened for delirium by trained, medically
qualified research team members using the confusion
assessment method (CAM),23 a well described and vali-
dated tool for this purpose, with reference to the notes
and discussion with treating team nursing, allied health
and medical staff where the diagnosis was not clear. Partic-
ipants could be included if delirium was diagnosed.
Patients were excluded if they were unable to understand
or communicate in English, had taken melatonin or a mel-
atonin receptor agonist within the preceding 14 days, were
unlikely to complete the trial – defined as an expected
prognosis or planned further admission to hospital of less
than 7 days, had a contraindication to melatonin (severe
hepatic failure, an active seizure disorder or concomitant
cimetidine use) or had an exclusively hypoactive delirium.
Randomisation and blinding
After applying inclusion and exclusion criteria, patients
were randomly allocated to treatment (5 mg melatonin)
or control (placebo) in a 1:1 ratio. Before the start of the
study an independent statistician generated randomised
allocation codes within permuted blocks of four patients
(two placebo and two treatment). The results were
unknown to any investigators, care-givers or administra-
tion staff. A separate code sheet was kept locked in the
trial pharmacy to allow matching after completion of the
trial and in the event of an adverse event where that
might be necessary.
Procedures
Patients received the study medication for five consecutive
nights at 8 pm. The study preparation contained either
melatonin 5 mg or placebo in identically packaged high-
density polyethylene containers of five capsules each.
Baseline data including age, sex, delirium severity,
smoking status, alcohol consumption, dementia status
through Informant Questionnaire on COgnitive Decline
in the Elderly, short form (IQCODE)24 and chart
review, comorbidities (Charlson Comorbidity Index25),
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psychiatric history including depressive symptoms,
premorbid function (Barthel index of activities of daily
living), medications and potential delirium precipitants –
classified as infectious/inflammatory, pain, metabolic –
were recorded. Electrolytes and liver function tests were
recorded for the same purpose. The motor subtype of
delirium was assessed by the clinical judgement of the
investigators due to the lack of a validated tool at the
start of the trial.
Following enrolment, patients were visited daily by
trained research staff for 7 days (5 days of medication
and 2 after completion) to collect primary and secondary
outcome and assess safety. Adverse events were reported
to an independent safety monitor for assessment for
severity and relationship to the intervention.
Objectives, outcomes and delirium
assessment
The first objective was to determine the feasibility of a
trial of oral Melatonin 5 mg nightly for five nights for
the treatment of delirium in older medical inpatients.
The second objective was to determine the number of
participants required to demonstrate a clinically and sta-
tistically significant decrease in the primary trial
outcome.
The primary trial outcome was delirium severity
assessed using the Memorial Delirium Assessment Scale
(MDAS).26 This was calculated from change in MDAS
scores from baseline to the average over Days 1–5 as a
marker of symptom severity. We had a priori defined a
clinically significant difference as 3 points improvement
on the MDAS, by comparison to the sole placebo con-
trolled trial of an antipsychotic (quetiapine, an accepted
treatment for delirium) for delirium demonstrating a
change of similar extent.27 MDAS is a validated scale,
scored from 0 to 30, positively correlated with severity
with good internal consistency and inter-rater reliability,












MMSE X X X
Digit Span Forwards and
Backwards
X X X
CAM X X X





Presence of restraints X X
Number of falls X X
Number of pressure areas X‡ X X
Rescue medication X X
Adverse events X X
Review INR X§ X§
†The IQCODE and CCI was measured at entry if possible but could be
measured at any point during the trial. ‡Initial number and location of
pressure areas was recorded at entry in order to derive the number of
new areas at each subsequent visit. §If participant was on warfarin, the
INR was performed every 1–2 days as per standard practice of the
treating team for acutely unwell inpatients when warfarinised. CAM,
confusion assessment method; CCI, Charlson Comorbidity Scale; D(#),
day number; INR, International Normalised Ratio; IQCODE, Informant
Questionnaire on Cognitive Decline in the Elderly; MDAS, Memorial
Delirium Assessment Scale; MMSE, mini-mental state examination.
Table 2 Baseline characteristics of the study participants
Characteristic Melatonin, n = 14 Placebo, n = 14
Age, mean  SD (years) 85.1  6.5 86.1  4.4
Female sex, n (%) 8 (61.5) 7 (46.7)
MDAS Day 0, mean  SD 14.4  6.7 16.7  4.6
Current smoker, n (%) 0 1 (6.7)
Ex smoker, n (%) 4(30.8) 2 (13.3)
Never smoked, n (%) 9 (69.2) 9 (60.0)
Alcohol use, n (%)
Excessive (>3 units/day) 0 0
Moderate (3–0 units/day) 4 (30.8) 3 (20.0)
None 9 (69.2) 9 (60.0)
Dementia, n (%)
History of dementia 6 (46.2) 8 (53.3)
IQCODE ≥3.45 6 (46.2) 10 (66.7)
IQCODE ≥3.45 and/or history 10 (76.9) 11 (73.3)
MMSE, mean  SD 8.7  5.7 12.6  8.8
History of delirium 0 (0) 2 (13.3)
Depression
History of depression, n (%) 4 (30.8) 0 (0)
CCI, mean  SD 6.1  1.8 6.2  1.3
Barthel index, mean  SD 16.2  5.5 14.9  5.2
Medications, n (%)
Anticholinergics 2 (15.4) 0 (0)
Opioids 4 (30.7) 2 (13.3)
Antipsychotics 1 (7.7) 2 (13.3)
Precipitating factors‡, n (%)
Inflammation or sepsis 8 (61.5) 6 (40.0)
Injury or pain 5 (38.5) 5 (33.3)
Metabolic 1 (7.7) 3 (20.0)
Cardiovascular 2 (15.3) 1 (6.7)
†Continuous variables assessed using Student’s t-test, categorical Fish-
er’s exact test (two sided). ‡Some patients had more than one precipi-
tating factor. CCI, Charlson Comorbidity Scale; IQCODE, Informant
Questionairre on Cognitive Decline in the Elderly; MDAS, Memorial Delir-
ium Assessment Scale; MMSE, mini-mental state.
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that is derived from scores on the Folstein Mini-Mental
State Examination,28 and Digit Span Forwards and Digit
Span Backwards.26
Secondary trial outcomes included the change in
mean MDAS scores over Days 1–5 (treatment period) to
the mean on Days 6–7, and delirium duration (number
of days CAM positive). Delirium presence or absence
was assessed daily by the CAM. Other secondary
outcomes were: a reduction in other delirium manage-
ment methods as measured by number of uses of
restraints and number and dose of rescue medications,
specifically benzodiazepines and antipsychotics, each
day, and sleep quality as assessed with item 10 of
the MDAS.
Safety outcomes were assessed by recording number
of falls and pressure areas occurring or developing dur-
ing active treatment (Table 1).
Power calculation
As one of the feasibility objectives was to obtain the stan-
dard deviation of the primary outcome measure to allow
a power calculation and the subsequent development of
an appropriately powered trial, a true power calculation
was unable to be performed.
Statistical analysis
Data were collected daily for 7 days. The primary and
secondary outcome measures were compared using a
Student’s t-test for normally distributed data or Mann–
Whitney test for non-normally distributed continuous
variables. Control and treatment group homogeneity
was tested with Chi-squared statistics. For discrete out-
comes, results were tested using a Chi-squared test. Where
expected cell counts were less than seven Fisher’s exact
test (two sided) substituted for Chi-squared test, with the
addition method used where cell counts were zero. The
missing data were handled for the analysis using the last









Change in MDAS baseline to
treatment




Change in MDAS treatment to
post-treatment
0.41  3.21 1.42
 2.90
0.196
Number of days CAM+, median
(IQR)
4.5 (3–5) 5 (5–5) 0.178
Number of falls Days 1–5 2 0 0.485
Number of new pressure areas
Days 1–5
0 0 1.000
Use of rescue medications Days
1–5
10 13 0.780
MDAS item 10 (sleep) Days 1–5,
mean  SD
1.23  0.23 1.63
 0.70
0.094
Use of restraints Days 1–5 0 0 1.000
†Continuous, normally distributed variables assessed using Student’s t-
test, non-normally distributed Wilcoxon rank-sum test, categorical Fish-
er’s exact test (two sided). CAM, confusion assessment method; IQR,
interquartile range; MDAS, Memorial Delirium Assessment Scale.
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observation carried forward method as per protocol.
A P-value of less than 0.05 was considered significant.
Results
One hundred and fifty-four potential participants were
assessed for eligibility. Eighty patients did not meet
inclusion or met exclusion criteria. Forty-five surrogate
decision-makers did not provide consent to participation,
with 29 potential inpatients randomised.
Table 2 shows the baseline characteristics of the inpa-
tients. The melatonin and placebo groups were well bal-
anced. Alcohol consumption was low in all groups
suggesting against alcohol withdrawal as a possible cause
of the presentation with delirium.
Figure 1 illustrates the flow of participants through the
trial. One participant in the placebo group succumbed to
a haemorrhagic stroke prior to receiving any interven-
tion but after enrolment so was excluded from the anal-
ysis. Five patients deceased during the trial, one in the
melatonin group, four in the placebo group. None was
assessed as related to the intervention. Four patients
were transferred out of the study site or discharged from
hospital prior to completion of trial procedures, three in
the melatonin group and one in the placebo group, for
9 out of 30 (31.0%) unable to complete in total. This
resulted in 11.0% of observations unavailable, a further
0.9% of observations were missing due to inability to
perform outcome measures during the trial – most often
when participants were not available due to attending
an investigation or procedure. Overall 11.9% of observa-
tions were unavailable, these were dealt with using the
last observation carried forward method. No participants
or their surrogate decision maker declined to participate
further once enrolled. The trial finished due to adequate
recruitment.
Baseline MDAS was lower in the melatonin group
(14.4  6.7 vs 16.7  4.6) suggesting lower delirium
severity, though not significantly (P = 0.247). The pri-
mary outcome, improvement in MDAS from baseline to
mean over Days 1–5, was not statistically significantly
different between the two groups (treatment 2.5  5.0
vs placebo 2.2  4.1, P = 0.413) 95% confidence inter-
vals (−7.5, 10) and (−6, 10.4). There was a trend to sig-
nificance in the mean MDAS item 10 (sleep disturbance
subscale, from 0 to 4) towards lower scores in the mela-
tonin group (1.2  0.2 vs 1.6  0.7, P = 0.094). None of
the safety-related outcomes was significantly different.
No adverse events related to melatonin use occurred.
Further results are displayed in Table 3.
Given the placebo group mean improvement in MDAS
of 2.1  4.1, and using a two sided calculation with an
alpha level of 0.05 and beta 0.9, two groups of
41 inpatients would be required to demonstrate a statis-
tically significant difference of 3 points on the MDAS
scale. Accounting for drop-out, 60 participants in each
group for a total number of 120 inpatients would be
required to demonstrate with 90% power that melato-
nin 5 mg reduces the severity of delirium over 5 days of
treatment by 3 points or more on MDAS.
Discussion
In this feasibility trial we demonstrated that treatment
with melatonin 5 mg for delirium in hospitalised older
medical inpatients is feasible. Improvement in MDAS
from baseline to mean over Days 1–5 was not statistically
significant between treatment and placebo groups.
A trend to less sleep disturbance was noted in the mela-
tonin group. The 95% confidence interval of the primary
outcome in the intervention group was (−7.5, 10) and
placebo (−6, 10.4), thus a range of possible hypotheses
are consistent with these results including: no effect of
melatonin, and superiority of melatonin over placebo at
the a priori level of 3 or more points. A definitive trial to
differentiate these hypotheses would require a total of
120 participants.
There is a strong need to develop effective treatment
for delirium as prevention cannot totally prevent the
incidence of delirium.29 Delirium in hospitalised patients
can be prevented through non-pharmacological
means;29,30 however, these methods have been trialled
in established delirium and found not to decrease sever-
ity or reduce duration in comparison to usual care.31
Delirium has a high prevalence at admission to hospital,1
therewith not all may be prevented. Therefore, there are
several patients with delirium that would benefit from
effective treatment. Delirium is a dangerous and dis-
tressing condition; there is an urgent need to find agents
and methods that can effectively and safely treat
delirium.32
Several treatments have been previously evaluated:
antipsychotics, melatonin and its agonists, and acetyl-
cholinesterase inhibitors. Antipsychotics have been
trialled for the management of symptoms of delirium,
but are not recommended in all cases of delirium.33
Quetiapine has been compared to placebo for the treat-
ment of delirium in general hospital inpatients with the
treated group improving faster but no significant
improvement on severity scores.27 Compared to placebo,
risperidone and haloperidol produced significantly worse
severity scores in palliative care patients with delirium.34
Other trials have been between antipsychotics or usual
care using benzodiazepines. In meta-analyses, antipsy-
chotics have been reported as either ineffective for treat-
ment35 or when divided into first (haloperidol) and
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second generation antipsychotics, second generation
antipsychotics have been reported as decreasing severity
and duration of delirium compared to haloperidol.36
Thus antipsychotics have been the most studied agent,
and may have a role in the treatment of delirium but this
is uncertain, they may be deleterious.
Given the important role of acetylcholine in delirium
and the deleterious role of anticholinergic drugs,
several uncontrolled trials and case reports suggested
rivastigmine37–41 and other acetylcholinesterase
inhibitors42–46 might be useful for delirium treatment or
prevention. However, a randomised double blinded con-
trolled trial of prophylactic rivastigmine oral solution in
cardiac surgery patients for delirium was negative.47
rivastigmine oral solution underwent evaluation in a
double blinded randomised controlled trial in delirium in
intensive care unit (ICU) for the treatment of delirium
with the hypothesis to increasing acetylcholine would
reduce the duration, but the trial was stopped early due
to an excess of deaths in the treatment arm,48 substan-
tially reducing interest of trials of this type, including a
trial under development by an author of this paper
(ACTRN12609001020279). Recently, a published trial of
rivastigmine topical patch for the prevention and treat-
ment of delirium in older patients with cognitive impair-
ment requiring hip fracture surgery demonstrated some
promising results with severity and incidence both
reduced, but the authors recommend further study49
and the result and safety should be confirmed in light of
previous results.
Melatonin holds promise as a safe medication with
few disease or medication interactions50 that may effec-
tively treat delirium in acutely unwell patients with
multi-morbidities. Case reports and series report treat-
ment efficacy, but this has not been evaluated in trials
designed for the evaluation of treatment of delirium to
reduce severity. Melatonin has been trialled for prophy-
laxis in doses of 0.5, 3 and 5 mg, and in those trials mela-
tonin was continued if delirium developed, giving some
indication regarding the ability of melatonin to reduce
the severity of delirium.19–21,51 In the 0.5 and 3 mg trials
no significant effect was demonstrated, and in the 5 mg
trial a validated scale of delirium severity was not used.
However, it may be that where melatonin treatment has
failed to prevent delirium it may also fail to decrease
severity. Current evidence does not support a role for
melatonin in the treatment of delirium severity though
this has not been appropriately evaluated. Ramelteon is
a melatonin receptor agonist with substantially more
potency at the melatonin receptor (estimated at 6–8
times as potent)52 that has a longer half-life than melato-
nin.53,54 Ramelteon has published case reports, series
and observational studies as a prophylactic55,56 and treat-
ment57,58 agent against delirium with some suggested
efficacy. Prophylaxis has been evaluated in placebo con-
trolled trial in elderly medical and ICU inpatients where
staff assessing outcomes and patients (but not treating
staff) were blinded to the treatment status and found to
significantly prevent delirium.59 A trial in ICU patients of
8 mg ramelteon daily showed decreased duration and
incidence of delirium though the primary outcome of
stay in ICU had only a statistical trend to improvement.60
Ramelteon has not been subject to a randomised con-
trolled trial for the treatment of delirium.
Strength and limitations
Strengths of this trial include the pragmatic design with
few exclusions of patients for medical reasons. Delirium
is a condition with many causes and overwhelmingly
affects patients with comorbidities, this has affected
enrolment in trials of medications with more potential
adverse effects resulting in slow recruitment.61 Lack of
surrogate consent was the reason for the low enrolment
of suitable inpatients. However, this rate of refusal is
consistent with other intervention trials for patients with
delirium.62 There is no evidence to suggest a systemic
bias as a result of this that might affect the generalis-
ability of results. A limitation of this study was the high
rate of drop-out. In this context of a pilot trial this assists
planning for a definitive trial and highlights the impor-
tance of finding an effective treatment for this highly
morbid condition.
Conclusion
In summary, antipsychotics have the most evidence for
the treatment of delirium but are not effective in all cases
and may be deleterious; acetylcholinesterase inhibitors,
melatonin and ramelteon are at this time not rec-
ommended for the treatment of delirium on the basis of
current evidence. A definitive trial of 5 mg melatonin
nightly for five nights for the treatment of delirium in
hospitalised elderly would add to the body of knowledge
regarding the treatment of delirium.
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